Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 6.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,569 shares of the specialty pharmaceutical company’s stock after selling 13,295 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Supernus Pharmaceuticals were worth $7,289,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. raised its holdings in shares of Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares during the period. Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock valued at $27,242,000 after buying an additional 40,968 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 1.1% during the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after acquiring an additional 7,833 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Supernus Pharmaceuticals by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock worth $14,449,000 after acquiring an additional 27,134 shares during the period.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last three months. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Up 0.3 %

Shares of SUPN opened at $31.26 on Friday. The firm has a market capitalization of $1.74 billion, a PE ratio of 29.22 and a beta of 0.83. The firm has a 50-day moving average price of $36.22 and a 200 day moving average price of $35.17. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent analyst reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.